This Article Full Text Full Text (PDF) All Versions of this Article: 40/10/e558    most recent STROKEAHA.109.559914v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Chavez, J. C. Articles by Feuerstein, G. Z. PubMed PubMed Citation Articles by Chavez, J. C. Articles by Feuerstein, G. Z. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Neuroprotectors

(Stroke. 2009;40:e558.)
© 2009 American Heart Association, Inc.

Comments, Opinions, and Review

Pharmacologic Interventions for Stroke

Looking Beyond the Thrombolysis Time Window Into the Penumbra With Biomarkers, Not a Stopwatch

Juan C. Chavez, MD; Orest Hurko, MD; Frank C. Barone, PhD Giora Z. Feuerstein, MD

From the Department of Translational Medicine (J.C.C., O.H., G.Z.F.), Wyeth Research, Collegeville, Pa; and the Department of Neurology (F.C.B.), SUNY Downstate Medical Center, Brooklyn, NY.

Correspondence to Juan C. Chavez, Wyeth Research, 500 Arcola Road, S-2348, Collegeville, PA 19426. E-mail chavezj{at}wyeth.com

Background and Purpose— The majority of pharmacological agents for stroke were developed based on the assumption that neurological deficits will be reduced upon the successful interruption of biochemical mechanisms leading to neuronal death. Despite significant evidence of preclinical efficacy, none of these agents succeeded. They either failed to demonstrate efficacy in the clinic or their development was halted for safety, strategic, or commercial reasons.

Summary of Review— This "neuroprotection strategy" has focused primarily on targets in the neurotoxic environment that occurs under ischemic conditions. In many cases, these agents were designed to tackle events that are known to start almost immediately after onset of ischemia, which is far before a realistic therapeutic time window opens for most, if not all, patients with stroke. In other instances, they were evaluated beyond a realistic timeframe in which one could expect significant salvageable tissue or penumbra to exist. Surprisingly, most of these agents were not evaluated in conjunction with strategies for improving perfusion to the affected tissue, indicating an overoptimistic assumption that neuroprotection alone could be sufficient to halt injury caused by an abrupt interruption of brain blood flow.

Conclusions— We provide a constructive translational medicine perspective about how one could improve the drug development process with the hope that the probability for success can increase in our quest to establish a novel therapy for stroke.

Key Words: biomarkers • drug development • ischemia • neuroprotection • translational medicine